<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34997314</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1433-7339</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>30</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer</Title>
          <ISOAbbreviation>Support Care Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A randomized double-blind feasibility study comparing cetirizine and diphenhydramine in the prevention of paclitaxel-associated infusion-related reactions: the PREMED-F1 study.</ArticleTitle>
        <Pagination>
          <StartPage>3389</StartPage>
          <EndPage>3399</EndPage>
          <MedlinePgn>3389-3399</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00520-021-06734-4</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Cetirizine is a less sedative alternative to diphenhydramine for the prevention of infusion-related reactions (IRR) to paclitaxel. However, its use remains controversial. In this study, we assessed feasibility for a future definitive non-inferiority trial comparing cetirizine to diphenhydramine as premedication to prevent paclitaxel-related IRR.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">This was a single-center randomized prospective feasibility study. Participants were paclitaxel-naive cancer patients scheduled to start paclitaxel chemotherapy. They were randomly assigned to receive either intravenous diphenhydramine 50 mg + oral placebo (control) or intravenous placebo + oral cetirizine 10 mg (intervention) for their first two paclitaxel treatments. The percentage of eligible patients completing a first paclitaxel treatment and the recruitment rate were assessed (feasibility outcomes). Drowsiness was measured at baseline and at selected time points using the Stanford Sleepiness Scale (SSS) (safety outcome). IRR events were also documented (efficacy outcome).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 37 eligible patients, 27 were recruited and randomized (control 13; intervention 14) and 25 completed the study. The recruitment rate was 4.8 participants/month, meeting the primary feasibility target. Drowsiness was the main adverse effect associated with the premedication. The increase in drowsiness compared to baseline (ΔSSS) was greater in the diphenhydramine group compared to the cetirizine group (median ΔSSS 2 (IQR 3.25) vs median ΔSSS 0 (IQR 1), p &lt; 0.01) when measured one hour after the premedication administration. One participant had an IRR and no unexpected serious adverse event occurred.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The trial methods were feasible in terms of recruitment, retention, and safety. Cetirizine was significantly less sedating than diphenhydramine. IRR were infrequent and a larger trial is warranted to confirm non-inferiority for IRR prevention.</AbstractText>
          <AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov, NCT04237090 (22.01.2020).</AbstractText>
          <CopyrightInformation>© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Beaucage-Charron</LastName>
            <ForeName>Johannie</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-8700-7728</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Hôpital Maisonneuve-Rosemont, 5415 Boul. l'Assomption, Montréal, Québec, H1T 2M4, Canada. johannie.beaucage-charron.cemtl@ssss.gouv.qc.ca.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Pharmacy, Université de Montréal, Montréal, Canada. johannie.beaucage-charron.cemtl@ssss.gouv.qc.ca.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gaudet</LastName>
            <ForeName>Laurence</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Hôpital Maisonneuve-Rosemont, 5415 Boul. l'Assomption, Montréal, Québec, H1T 2M4, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Pharmacy, Université de Montréal, Montréal, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lamothe</LastName>
            <ForeName>Sarah</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Hôpital Maisonneuve-Rosemont, 5415 Boul. l'Assomption, Montréal, Québec, H1T 2M4, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Pharmacy, Université de Montréal, Montréal, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pelletier</LastName>
            <ForeName>Cloé</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Hôpital Maisonneuve-Rosemont, 5415 Boul. l'Assomption, Montréal, Québec, H1T 2M4, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Pharmacy, Université de Montréal, Montréal, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pépin</LastName>
            <ForeName>Anne-Sophie</ForeName>
            <Initials>AS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Hôpital Maisonneuve-Rosemont, 5415 Boul. l'Assomption, Montréal, Québec, H1T 2M4, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Pharmacy, Université de Montréal, Montréal, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Roy</LastName>
            <ForeName>Valérie</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Hôpital Maisonneuve-Rosemont, 5415 Boul. l'Assomption, Montréal, Québec, H1T 2M4, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Pharmacy, Université de Montréal, Montréal, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Charpentier</LastName>
            <ForeName>Frédéric</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Hôpital Maisonneuve-Rosemont, 5415 Boul. l'Assomption, Montréal, Québec, H1T 2M4, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lordkipanidzé</LastName>
            <ForeName>Marie</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Pharmacy, Université de Montréal, Montréal, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Research Center, Montreal Heart Institute, Montréal, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Projean</LastName>
            <ForeName>Denis</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Hôpital Maisonneuve-Rosemont, 5415 Boul. l'Assomption, Montréal, Québec, H1T 2M4, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bouchard</LastName>
            <ForeName>Philippe</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Hôpital Maisonneuve-Rosemont, 5415 Boul. l'Assomption, Montréal, Québec, H1T 2M4, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Picard</LastName>
            <ForeName>Matthieu</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Clinical Immunology and Allergy, Department of Medecine, Hôpital Maisonneuve-Rosemont, Montréal, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Medecine, Université de Montréal, Montréal, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT04237090</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Support Care Cancer</MedlineTA>
        <NlmUniqueID>9302957</NlmUniqueID>
        <ISSNLinking>0941-4355</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>8GTS82S83M</RegistryNumber>
          <NameOfSubstance UI="D004155">Diphenhydramine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>P88XT4IS4D</RegistryNumber>
          <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YO7261ME24</RegistryNumber>
          <NameOfSubstance UI="D017332">Cetirizine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017332" MajorTopicYN="Y">Cetirizine</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004155" MajorTopicYN="N">Diphenhydramine</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017239" MajorTopicYN="Y">Paclitaxel</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011292" MajorTopicYN="N">Premedication</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cetirizine</Keyword>
        <Keyword MajorTopicYN="N">Diphenhydramine</Keyword>
        <Keyword MajorTopicYN="N">Drug hypersensitivity</Keyword>
        <Keyword MajorTopicYN="N">Paclitaxel</Keyword>
        <Keyword MajorTopicYN="N">Premedication</Keyword>
      </KeywordList>
      <CoiStatement>The authors have no conflicts of interest to declare that are relevant to the content of this article. Marie Lordkipanidzé was supported by the Fonds de recherche du Québec en Santé Junior 1 Research Scholarship (33048) and is a Canada Research Chair in Platelets as biomarkers and vectors (950–232706).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>8</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34997314</ArticleId>
        <ArticleId IdType="pmc">PMC8741567</ArticleId>
        <ArticleId IdType="doi">10.1007/s00520-021-06734-4</ArticleId>
        <ArticleId IdType="pii">10.1007/s00520-021-06734-4</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al.  Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8:1263–1268. doi: 10.1200/jco.1990.8.7.1263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.1990.8.7.1263</ArticleId>
            <ArticleId IdType="pubmed">1972736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Donehower RC, Rowinsky EK, Grochow LB, Longnecker SM, Ettinger DS. Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep. 1987;71:1171–1177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2891441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Picard M, Castells MC. Re-visiting hypersensitivity reactions to taxanes: a comprehensive review. Clin Rev Allergy Immunol. 2015;49:177–191. doi: 10.1007/s12016-014-8416-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12016-014-8416-0</ArticleId>
            <ArticleId IdType="pubmed">24740483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pfizer Canada ULC (2020) Product monograph: paclitaxel for injection</Citation>
        </Reference>
        <Reference>
          <Citation>Picard M. Management of hypersensitivity reactions to taxanes. Immunol Allergy Clin North Am. 2017;37:679–693. doi: 10.1016/j.iac.2017.07.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.iac.2017.07.004</ArticleId>
            <ArticleId IdType="pubmed">28965634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pharmaceutical Partners of Canada Inc (2012) Package insert: Diphenhydramine hydrochloride injection USP</Citation>
        </Reference>
        <Reference>
          <Citation>Estelle R, Simons F, Akdis CA (2008) Histamine and H1 Antihistamines. In: Franklin Adkinson Jr N, Busse W, Bochner B, Holgate S, Estelle Simons F, Lemanske R (ed) Middleton’s Allergy: Principles and Practice, 7th edn. Elsevier Health Sciences, pp 1517–1548</Citation>
        </Reference>
        <Reference>
          <Citation>Kalivas J, Breneman D, Tharp M, Bruce S, Bigby M. Urticaria: clinical efficacy of cetirizine in comparison with hydroxyzine and placebo. J Allergy Clin Immunol. 1990;86:1014–1018. doi: 10.1016/s0091-6749(05)80246-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0091-6749(05)80246-5</ArticleId>
            <ArticleId IdType="pubmed">1979796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Belaich S, Bruttmann G, DeGreef H, Lachapelle JM, Paul E, Pedrali P, et al.  Comparative effects of loratadine and terfenadine in the treatment of chronic idiopathic urticaria. Ann Allergy. 1990;64:191–194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1967919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simons FE, McMillan JL, Simons KJ. A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppresive effects on histamine-induced wheals and flares during 24 hours in normal subjects. J Allergy Clin Immunol. 1990;86:540–547. doi: 10.1016/0091-6749(90)90091-H.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0091-6749(90)90091-H</ArticleId>
            <ArticleId IdType="pubmed">1977781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fein MN, Fischer DA, O’Keefe AW, Sussman GL. CSACI position statement: newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria. Allergy Asthma Clin Immunol. 2019;15:1–6. doi: 10.1186/s13223-019-0375-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13223-019-0375-9</ArticleId>
            <ArticleId IdType="pmc">PMC6320604</ArticleId>
            <ArticleId IdType="pubmed">30622569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siderov J, Wendel N, Davis ID. Non-sedating antihistamines for premedication in ambulatory oncology patients. J Pharm Pract Res. 2002;32:108–109. doi: 10.1002/jppr2002322108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jppr2002322108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Durham CG, Thotakura D, Sager L, Foster J, Herrington JD. Cetirizine versus diphenhydramine in the prevention of chemotherapy-related hypersensitivity reactions. J Oncol Pharm Pract. 2019;25:1396–1401. doi: 10.1177/1078155218811505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1078155218811505</ArticleId>
            <ArticleId IdType="pubmed">30419768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>National Institutes of Health, National Cancer Institute (2017) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0</Citation>
        </Reference>
        <Reference>
          <Citation>McNeil Consumer Healthcare (2017) Product monograph: reactine, reactine fast melt junior, reactine rapid dissolve, reactine allergy liquid gels</Citation>
        </Reference>
        <Reference>
          <Citation>Petersen LJ, Church MK, Rihoux JP, Skov PS. Measurement of interstitial cetirizine concentrations in human skin: correlation of drug levels with inhibition of histamine-induced skin responses. Allergy. 1999;54:607–611. doi: 10.1034/j.1398-9995.1999.00038.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1034/j.1398-9995.1999.00038.x</ArticleId>
            <ArticleId IdType="pubmed">10435475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boulanger J, Boursiquot JN, Cournoyer G, Lemieux J, Masse MS, Almanric K, et al.  Management of hypersensitivity to platinum- and taxane-based chemotherapy: CEPO review and clinical recommendations. Curr Oncol. 2014;21:e630–641. doi: 10.3747/co.21.1966.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3747/co.21.1966</ArticleId>
            <ArticleId IdType="pmc">PMC4117628</ArticleId>
            <ArticleId IdType="pubmed">25089112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banerji A, Long AA, Camargo CA. Diphenhydramine versus nonsedating antihistamines for acute allergic reactions: a literature review. Allergy Asthma Proc. 2007;28:418–426. doi: 10.2500/aap.2007.28.3015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2500/aap.2007.28.3015</ArticleId>
            <ArticleId IdType="pubmed">17883909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasko P, Rodacki T, Domagala-Rodacka R, Palimonka K, Marcinkowska M, Owczarek D. Second generation H1 - antihistamines interaction with food and alcohol—a systematic review. Biomed Pharmacother. 2017;93:27–39. doi: 10.1016/j.biopha.2017.06.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2017.06.008</ArticleId>
            <ArticleId IdType="pubmed">28622592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoddes E, Zarcone V, Smythe H, Phillips R, Dement WC. Quantification of sleepiness: a new approach. Psychophysiology. 1973;10:431–436. doi: 10.1111/j.1469-8986.1973.tb00801.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1469-8986.1973.tb00801.x</ArticleId>
            <ArticleId IdType="pubmed">4719486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract. 2004;10:307–312. doi: 10.1111/j.2002.384.doc.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.2002.384.doc.x</ArticleId>
            <ArticleId IdType="pubmed">15189396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Billingham SA, Whitehead AL, Julious SA. An audit of sample sizes for pilot and feasibility trials being undertaken in the United Kingdom registered in the United Kingdom Clinical Research Network database. BMC Med Res Methodol. 2013;13:104. doi: 10.1186/1471-2288-13-104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2288-13-104</ArticleId>
            <ArticleId IdType="pmc">PMC3765378</ArticleId>
            <ArticleId IdType="pubmed">23961782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Julious S. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat. 2005;4:287–291. doi: 10.1002/pst.185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pst.185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eldridge SM, Lancaster GA, Campbell MJ, Thabane L, Hopewell S, Coleman CL, et al.  Defining feasibility and pilot studies in preparation for randomised controlled trials: development of a conceptual framework. PLoS ONE. 2016;11:e0150205. doi: 10.1371/journal.pone.0150205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0150205</ArticleId>
            <ArticleId IdType="pmc">PMC4792418</ArticleId>
            <ArticleId IdType="pubmed">26978655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walters SJ, Dos Anjos B, Henriques-Cadby I, Bortolami O, Flight L, Hind D, Jacques RM, et al.  Recruitment and retention of participants in randomised controlled trials: a review of trial funded and published by the United Kingdom Health Technology Assessment Programme. BMJ Open. 2017;7:e015276. doi: 10.1136/bmjopen-2016-015276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmjopen-2016-015276</ArticleId>
            <ArticleId IdType="pmc">PMC5372123</ArticleId>
            <ArticleId IdType="pubmed">28320800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Avis N, Smith K, Link C, Hortobagyi GN, Rivera E. Factors associated with participation in breast cancer clinical trials. J Clin Oncol. 2006;24:1860–1867. doi: 10.1200/jco.2005.03.8976.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2005.03.8976</ArticleId>
            <ArticleId IdType="pubmed">16622260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kay GG. The effects of antihistamines on cognition and performance. J Allergy Clin Immunol. 2000;105:s622–627. doi: 10.1067/mai.2000.106153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1067/mai.2000.106153</ArticleId>
            <ArticleId IdType="pubmed">10856168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Efird J. Blocked randomization with randomly selected block sizes. Int J Environ Res Public Health. 2011;8:15–20. doi: 10.3390/ijerph8010015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijerph8010015</ArticleId>
            <ArticleId IdType="pmc">PMC3037057</ArticleId>
            <ArticleId IdType="pubmed">21318011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maldonado CC, Bentley AJ, Mitchell D. A pictorial sleepiness scale based on cartoon faces. Sleep. 2004;27:541–548. doi: 10.1093/sleep/27.3.541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/sleep/27.3.541</ArticleId>
            <ArticleId IdType="pubmed">15164912</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
